PURCHASE, N.Y., January 2, 2008 – Nutrition 21, Inc. (NASDAQ: NXXI) today announced that it received a Nasdaq Staff letter that states that the Company has failed to comply with the $1.00 minimum bid price requirement for continued listing set forth in Marketplace Rule 4310(c)(4), and that the Company is being provided 180 calendar days, or until June 23, 2008, to regain compliance. If the Company continues to meet all other listing requirements as of June 23, 2008, the Company will be granted an additional 180 calendar days to regain compliance with the minimum bid price requirement. If the Company does not regain compliance with the minimum bid price requirement, the Company will be notified that its securities will be delisted.  If the Company is notified of delisting, the Company may appeal.

About Nutrition 21
Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21’s portfolio of health and wellness brands include: Chromax®, Core4Life™ Advanced Memory Formula™, Diabetes Essentials™, Iceland Health® Maximum Strength Omega-3 and Iceland Health® Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally.  For more information please visit http://www.nutrition21.com.

# # #